Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Nausea and Vomiting (CINV)
Conditions
Chemotherapy-Induced Nausea and Vomiting (CINV)
Trial Timeline
Sep 24, 2012 → Nov 3, 2014
NCT ID
NCT01594749About Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue Therapy is a phase 3 stage product being developed by Merck for Chemotherapy-Induced Nausea and Vomiting (CINV). The current trial status is completed. This product is registered under clinical trial identifier NCT01594749. Target conditions include Chemotherapy-Induced Nausea and Vomiting (CINV).
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Nausea and Vomiting (CINV) were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01594749 | Phase 3 | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Nausea and Vomiting (CINV)